Apelin in acute myocardial infarction and heart failure induced by ischemia

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 406-410

  Tycinska, Agnieszka M ^a   Lisowska, Anna ^a   Musial, Wlodzimierz J ^a   Sobkowicz, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

AMI; Apelin; Heart failure

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APELIN; APELIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1;

ACUTE HEART INFARCTION; CARDIAC RESYNCHRONIZATION THERAPY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG TARGETING; GENE EXPRESSION; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE DISEASE; ANIMALS; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA;

ANIMALIA;

EID: 84355161822     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.021     Document Type: Review

References (51)

1. Guzik T.J., Mangalat D., Korbut R. Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol 2006, 57:505-528.
2. Wozniak S.E., Gee L.L., Wachtel M.S., Frezza E.E. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54:1847-1856.
3. O'Dowd B.F., Heiber M., Chan A., et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993, 136:355-360.
4. Civelli O., Nothacker H., Saito Y., Wang Z., Lin S.H., Reinscheid R.K. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors. Trends Neurosci 2001, 24:230-237.
5. Tatemoto K., Hosoya M., Habata Y., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998, 251:471-476.
6. Lee D.K., Cheng R., Nguyen T., et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000, 74:34-41.
7. Kawamata Y., Habata Y., Fukusumi S., et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001, 1538:162-171.
8. Kleinz M.J., Davenport A.P. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005, 107:198-211.
9. Masri B., Knibiehler B., Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 2005, 17:415-426.
10. Reaux-Le Goazigo A., Morinville A., Burlet A., Llorens-Cortes C., Beaudet A. Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology 2004, 145:4392-4400.
11. Szokodi I., Tavi P., Fóldes G., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002, 91:434-440.
12. Tatemoto K., Takayama K., Zou M.X., et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2011, 99:87-92.
13. De Mota N., Goazigo A.R.L., El Messari S., et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 2004, 101:10464-10469.
14. Ishida J., Hashimoto T., Hashimoto Y., et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004, 279:26274-26279.
15. Zhong J.C., Yu X.Y., Huang Y., Yung L.M., Lau C.W., Lin S.G. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 2007, 74:388-395.
16. Daviaud D., Boucher J., Gesta S., et al. TNFα up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006, 20:1528-1530.
17. Boucher J., Masri B., Daviaud D., et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005, 146:1764-1771.
18. Fóldes G., Horkay F., Szokodi I., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003, 308:480-485.
19. Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003, 108:1432-1439.
20. Del Ry S., Cabiati M., Raucci S., et al. Sequencing and cardiac expression of apelin in Sus scrofa. Pharmacol Res 2009, 60:314-319.
21. Chamberland C., Barajas-Martinez H., Haufe V., et al. Modulation of canine cardiac sodium current by Apelin. J Mol Cell Cardiol 2010, 48:694-701.
22. Ronkainen V.P., Ronkainen J.J., Hánninen S.L., et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 2007, 21:1821-1830.
23. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992, 12:5447-5454.
24. Cormier-Regard S., Nguyen S.V., Claycomb W.C. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 1998, 273:17787-17792.
25. Chun Y.S., Hyun J.Y., Kwak Y.G., et al. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 2003, 370:149-157.
26. Sheikh A., Chun H., Glassford A., et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 2008, 294:H88-H98.
27. Atluri P., Morine K.J., Liao G.P., et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 2007, 12:127-138.
28. Jia Y.X., Pan C.S., Zhang J., et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 2006, 133:147-154.
29. Kido M., Du L., Sullivan C.C., et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005, 46:2116-2124.
30. Kleinz M.J., Baxter G.F. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 2008, 146:271-277.
31. Gao L.R., Zhang N.K., Bai J., et al. The apelin-APJ pathway exists in cardiomyogenic cells derived from mesenchymal stem cells in vitro and in vivo. Cell Transplant 2010, 19:949-958.
32. Pitkin S.L., Maguire J.J., Kuc R.E., Davenport A.P. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 2010, 160:1785-1795.
33. Ringstróm C., Dekker Nitert M., Bennet H., et al. Apelin is a novel islet peptide. Regul Pept 2010, 162:44-51.
34. Berry M.F., Pirolli T.J., Jayasankar V., et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004, 110(11 Suppl. 1):II187-II193.
35. Ashley E.A., Powers J., Chen M., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005, 65:73-82.
36. Japp A.G., Cruden N.L., Amer D.A.B., et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008, 52:908-913.
37. Tycinska A.M., Sobkowicz B., Mroczko B., et al. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta 2010, 411:2014-2018.
38. Kuklinska A.M., Sobkowicz B., Sawicki R., et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 2010, 25:363-367.
39. Weir R.A., Chong K.S., Dalzell J.R., et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 2009, 11:551-558.
40. Kadoglou N.P., Lampropoulos S., Kapelouzou A., et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease - KOZANI STUDY. Transl Res 2010, 155:238-246.
41. Li Z., Bai Y., Hu J. Reduced apelin levels in stable angina. Intern Med 2008, 47:1951-1955.
42. Kagiyama S., Fukuhara M., Matsumura K., Lin Y., Fujii K., Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 2005, 125:55-59.
43. Iwanaga Y., Kihara Y., Takenaka H., Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006, 41:798-806.
44. Zeng X.J., Zhang L.K., Wang H.X., Lu L.Q., Ma L.Q., Tang C.S. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009, 30:1144-1152.
45. Rastaldo R., Cappello S., Folino A., et al. Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol 2011, 300:H2308-H2315.
46. Francia P., Salvati A., Balla C., et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 2007, 9:306-309.
47. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992, 44:479-602.
48. Chong K.S., Gardner R.S., Morton J.J., Ashley E.A., McDonagh T.A. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006, 8:355-360.
49. Goetze J.P., Rehfeld J.F., Carlsen J., et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006, 133:134-138.
50. Miettinen K.H., Magga J., Vuolteenaho O., et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept 2007, 140:178-184.
51. Japp A.G., Cruden N.L., Barnes G., et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010, 121:1818-1827.